Literature DB >> 23306823

The effects of organic nitrates on osteoporosis: a systematic review.

S A Jamal1, L S Reid, C J Hamilton.   

Abstract

Current treatments for osteoporosis are limited by lack of effect on cortical bone, side effects, and, in some cases, cost. Organic nitrates, which act as nitric oxide donors, may be a potential alternative. This systematic review summarizes the clinical data that reports on the effects of organic nitrates and bone. Organic nitrates, which act as nitric oxide donors, are novel agents that have several advantages over the currently available treatments for osteoporosis. This systematic review summarizes the clinical data that reports on the effects of organic nitrates on bone. We searched Medline (1966 to November 2012), EMBASE (1980 to November 2012), and the Cochrane Central Register of Controlled Trials (Issue 11, 2012). Keywords included nitrates, osteoporosis, bone mineral density (BMD), and fractures. We identified 200 citations. Of these, a total of 29 were retrieved for more detailed evaluation and we excluded 19 manuscripts: 15 because they did not present original data and four because they did not provide data on the intervention or outcome of interest. As such, we included ten studies in literature review. Of these ten studies two were observational cohort studies reporting nitrate use was associated with increased BMD; two were case control studies reporting that use of nitrates were associated with lower risk of hip fracture; two were randomized controlled trials (RCT) comparing alendronate to organic nitrates for treatment of postmenopausal women and demonstrating that both agents increased lumbar spine BMD. The two largest RCT with the longest follow-up, both of which compared effects of organic nitrates to placebo on BMD in women without osteoporosis, reported conflicting results. Headaches were the most common adverse event among women taking nitrates. No studies have reported on fracture efficacy. Further research is needed before recommending organic nitrates for the treatment of postmenopausal osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23306823     DOI: 10.1007/s00198-012-2262-9

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  48 in total

1.  Nitrate use and changes in bone mineral density: the Canadian Multicentre Osteoporosis Study.

Authors:  S A Jamal; D Goltzman; D A Hanley; A Papaioannou; J C Prior; R G Josse
Journal:  Osteoporos Int       Date:  2008-09-18       Impact factor: 4.507

Review 2.  The Michael Mason Prize Essay 1997. Nitric oxide and bone: what a gas!

Authors:  S H Ralston
Journal:  Br J Rheumatol       Date:  1997-08

3.  Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial.

Authors:  Sophie A Jamal; Douglas C Bauer; Kristine E Ensrud; Jane A Cauley; Marc Hochberg; Areef Ishani; Steven R Cummings
Journal:  J Bone Miner Res       Date:  2007-04       Impact factor: 6.741

4.  Inhibition of avian osteoclast bone resorption by monoclonal antibody 121F: a mechanism involving the osteoclast free radical system.

Authors:  P Collin-Osdoby; L Li; L Rothe; F Anderson; D Kirsch; M J Oursler; P Osdoby
Journal:  J Bone Miner Res       Date:  1998-01       Impact factor: 6.741

5.  Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial.

Authors:  D C Bauer; D Black; K Ensrud; D Thompson; M Hochberg; M Nevitt; T Musliner; D Freedholm
Journal:  Arch Intern Med       Date:  2000-02-28

6.  Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents.

Authors:  Marc C Hochberg; Susan Greenspan; Richard D Wasnich; Paul Miller; Desmond E Thompson; Philip D Ross
Journal:  J Clin Endocrinol Metab       Date:  2002-04       Impact factor: 5.958

7.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Authors:  B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

8.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

9.  Intermittent use of nitrates increases bone mineral density: the study of osteoporotic fractures.

Authors:  S A Jamal; W S Browner; D C Bauer; S R Cummings
Journal:  J Bone Miner Res       Date:  1998-11       Impact factor: 6.741

10.  Isosorbide mononitrate increases bone formation and decreases bone resorption in postmenopausal women: a randomized trial.

Authors:  Sophie A Jamal; Steven R Cummings; Gillian A Hawker
Journal:  J Bone Miner Res       Date:  2004-07-26       Impact factor: 6.741

View more
  7 in total

Review 1.  The Key Role of the Blood Supply to Bone.

Authors:  Massimo Marenzana; Timothy R Arnett
Journal:  Bone Res       Date:  2013-09-25       Impact factor: 13.567

2.  Urinary heavy metals, phthalates, phenols, thiocyanate, parabens, pesticides, polyaromatic hydrocarbons but not arsenic or polyfluorinated compounds are associated with adult oral health: USA NHANES, 2011-2012.

Authors:  Ivy Shiue
Journal:  Environ Sci Pollut Res Int       Date:  2015-05-28       Impact factor: 4.223

3.  Serum urate levels and the risk of hip fractures: data from the Cardiovascular Health Study.

Authors:  Tapan Mehta; Petra Bůžková; Mark J Sarnak; Michel Chonchol; Jane A Cauley; Erin Wallace; Howard A Fink; John Robbins; Diana Jalal
Journal:  Metabolism       Date:  2014-11-21       Impact factor: 8.694

Review 4.  NADPH oxidases in bone homeostasis and osteoporosis.

Authors:  Katrin Schröder
Journal:  Cell Mol Life Sci       Date:  2014-08-29       Impact factor: 9.261

Review 5.  NO-Rich Diet for Lifestyle-Related Diseases.

Authors:  Jun Kobayashi; Kazuo Ohtake; Hiroyuki Uchida
Journal:  Nutrients       Date:  2015-06-17       Impact factor: 5.717

Review 6.  Nitric oxide donors and selective carbonic anhydrase inhibitors: a dual pharmacological approach for the treatment of glaucoma, cancer and osteoporosis.

Authors:  Simone Carradori; Adriano Mollica; Celeste De Monte; Arianna Ganese; Claudiu T Supuran
Journal:  Molecules       Date:  2015-03-31       Impact factor: 4.411

7.  The anabolic action of intermittent parathyroid hormone on cortical bone depends partly on its ability to induce nitric oxide-mediated vasorelaxation in BALB/c mice.

Authors:  S Gohin; A Carriero; C Chenu; A A Pitsillides; T R Arnett; M Marenzana
Journal:  Cell Biochem Funct       Date:  2016-02-01       Impact factor: 3.685

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.